Ludwig Center for Cancer Immunotherapy: Selected Publications

Immunotherapy Trial Development

Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26.

Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with CTLA-4 blockade to reject preimplanted tumors. Cancer Res. 2009 Oct 1;69(19):7747-55. Epub 2009 Sep 8.

Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009 Jul;157(1):9-19. Epub 2009 Feb 18.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas K, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN. Self-antigen specific CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response. J Exp Med. 2009; 206(4):849-66.

Duan F, LinY, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli SL, Wolchok JD, and Houghton AN. Immune rejection of mouse tumors expressing mutated self. Cancer Research. 2009; 69(8):3545-53.

Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med. 2009; 206(5):1103-16.

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010 Mar 15;207(3):637-50. Epub 2010Feb 15.

Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):266-71. Epub 2010 Dec 20.

Immune Monitoring

Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun. 2009 Jun 5;9:5.

Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu YY, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009;11(7): 912-22.

Yuan J, Ku GY, Page DB, Scheroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after two doses correlates with survival. Cancer. 2010 Apr 1;16(7):1767-75. (First two authors contribute equally to this study.)

Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ,Wolchok JD. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun. 2010 Jan 7;10:1. Erratum in: Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added].

Targeted Radioimmunotherapy and Diagnosis

Schwartz J, Jaggi JS, O’Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011 Feb 7;56(3):721-33.

Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010 Nov 1;16(21):5288-95.

Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One. 2010 May 27;5(5):e10857.